PLRX Company Profile and Key Details
Pliant Therapeutics, Inc.
PLRX Stock Price Chart
Stock Price Today
Pliant Therapeutics, Inc. (PLRX) stock surged +1.65%, trading at $11.10 on NASDAQ, up from the previous close of $10.92. The stock opened at $10.74, fluctuating between $10.73 and $11.12 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Company Information
| Employees | 166 |
| Beta | 1.09 |
| Sales or Revenue | $1.58M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Pliant Therapeutics, Inc. (NASDAQ: PLRX) stock price is $11.10 in the last trading session. During the trading session, PLRX stock reached the peak price of $11.12 while $10.73 was the lowest point it dropped to. The percentage change in PLRX stock occurred in the recent session was 1.65% while the dollar amount for the price change in PLRX stock was $0.18.
The NASDAQ listed PLRX is part of Biotechnology industry that operates in the broader Healthcare sector. Pliant Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Mike Ouimette
Gen. Counsel & Corporation Sec.
Mr. Hal Chapman M.D.
Scientific Founder & Member of Scientific Advisory Board
Dr. Rik Derynck
Scientific Founder & Member of Scientific Advisory Board
Mr. Johannes P. Hull
Chief Bus. Officer
Mr. Bill DeGrado Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Dr. Keith Lamont Cummings M.B.A., M.D.
Chief Financial Officer
Dr. Éric Lefebvre M.D.
Chief Medical Officer
Mr. Craig D. Muir
Interim Chief Technology Officer
Mr. Dean Sheppard M.D.
Scientific Founder & Member of Scientific Advisory Board
Mr. Mike Ouimette J.D.
Gen. Counsel & Corporation Sec.
Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D.
Pres, Chief Executive Officer & Director
PLRX's closing price is 6.85% higher than its 52-week low of $10.22 where as its distance from 52-week high of $18.92 is -42.28%.
Number of PLRX employees currently stands at 166.
Official Website of PLRX is: https://pliantrx.com
PLRX could be contacted at phone 650 481 6770 and can also be accessed through its website. PLRX operates from 260 Littlefield Avenue, South San Francisco, CA 94080, United States.
PLRX stock volume for the day was 374.33K shares. The average number of PLRX shares traded daily for last 3 months was 508.57K.
The market value of PLRX currently stands at $675.47M with its latest stock price at $11.10 and 60.85M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com